The safety of novel gut peptide ghrelin for the treatment of chronic kidney disease
Phase 1
- Conditions
- Chronic kidney disease
- Registration Number
- JPRN-UMIN000011673
- Lead Sponsor
- Keio University, Scool of Medicine, Division of nephrology, endocrinology, and metabolism
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Not provided
Exclusion Criteria
1. subjects with severe liver dysfunction 2. subjects with neoplasma 3. subjects with severe infection 4. subjects with psychogenic disorder 5. sujects with allergic reaction to wheat, egg, and milk 6. pregnant women 7. subjects tha were not egligble for the stusy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The temporal change of plasma concentration of ghrelin after the iv infusion
- Secondary Outcome Measures
Name Time Method Change of eGFR Anthropodic change Renal function Metabolic marker Oxidative stressmarker Nutrition status Adverse effects by ghrelin infusion